Guidelinevery high evidence
Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.
Journal of the American College of Cardiology·June 9, 2026·PMID 42263012
Why it mattersThis statement operationalizes the 2026 CKM guideline by detailing how to use the PREVENT equations to personalize primary prevention. It helps clinicians move beyond single-disease risk scores to a comprehensive CKM framework, directly informing decisions on initiating and intensifying therapies for hypertension, dyslipidemia, obesity, diabetes, and chronic kidney disease.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled